Form 4: Catalyst Pharma Legal Officer Exercises, Sells Shares

Catalyst Pharmaceuticals' Chief Compliance/Legal Officer, Brian Elsbernd, exercised stock options and subsequently sold a total of 50,000 common shares for personal reasons.

Summary

• Brian Elsbernd, Chief Compliance/Legal Officer of Catalyst Pharmaceuticals, Inc. (CPRX), reported transactions involving the company's common stock and options.
• On September 3, 2025, Mr. Elsbernd exercised options to acquire 20,000 shares of common stock at an exercise price of $2.24 per share.
• Immediately following the exercise on September 3, 2025, he sold 20,000 shares of common stock on the open market at a weighted average price of $20.08 per share, ranging from $20.035 to $20.13.
• On September 4, 2025, he exercised options to acquire an additional 30,000 shares of common stock at an exercise price of $2.24 per share.
• Following this exercise on September 4, 2025, he sold 30,000 shares of common stock on the open market at a weighted average price of $19.52 per share, ranging from $19.325 to $19.73.
• The sales were stated to be for personal reasons and not due to any disagreement with the company.
• After these transactions, Mr. Elsbernd's direct beneficial ownership of common stock decreased from 208,564 shares to 188,564 shares.
• His direct beneficial ownership of options to purchase common stock decreased from 989,084 to 959,084.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to insider selling, even though it's for personal reasons and the officer profited significantly from exercising options. A reduction in insider ownership can sometimes be viewed with caution by investors.

Positives

• The exercise of options at a low price ($2.24) and subsequent sale at significantly higher market prices (average $20.08 and $19.52) indicates a substantial profit for the reporting person, reflecting the value of the company's stock performance.
• The options were deeply in-the-money, suggesting the company's stock has performed well since the options were granted.

Negatives

• The transactions resulted in a net reduction of 50,000 shares in the Chief Compliance/Legal Officer's direct beneficial ownership of common stock, which can sometimes be perceived negatively by investors as it reduces insider alignment.
• While stated for personal reasons, insider selling can occasionally lead to questions about management's long-term confidence, despite the explicit disclaimer.

Management Comments

• "Shares were sold on the open market for personal reasons and not as a result of a disagreement with the Company."

Stakeholder Impact

• Shareholders may view the reduction in insider ownership as a minor negative, potentially impacting investor confidence, although the stated reason of 'personal reasons' attempts to mitigate this.

Key Dates

Recommendation

While the insider profited significantly from exercising options, the subsequent sale of shares reduces their direct beneficial ownership. This is a minor negative signal, but not substantial enough on its own to warrant a 'sell' recommendation. Investors should 'hold' and monitor future insider activity and company performance.

Keywords

CPRX, Catalyst Pharmaceuticals, Insider Transaction, Form 4, Stock Options, Share Sale, Brian Elsbernd, Chief Compliance Officer